Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf ·...
Transcript of Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf ·...
![Page 1: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/1.jpg)
Quality Control Strategies in Continuous Manufacturing
Fernando J. Muzzio, Distinguished ProfessorDepartment of Chemical and Biochemical Engineering,
Rutgers University, NJ, USAPresented at CCPMJDecember 12, 2018
1
![Page 2: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/2.jpg)
Advanced Manufacturing
• Advanced manufacturing is:– Predictively designed– Automated– Optimized– Scalable– Transferable/portable
– ACHIEVABLE
![Page 3: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/3.jpg)
Contents• Historical Background: C-SOPS and CM• What does it take to implement CM?• Collaborations with FDA• The Janssen Partnership• The GSK Partnership• The Powder Process Engineering Toolbox • Modes of Interaction• Conclusions
![Page 4: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/4.jpg)
Rutgers/C-SOPS’ engineering approach and industrial engagement model has created an engagement sandbox whereindustry, academia, and regulators come together on continuous pharmaceutical manufacturing.
Working with industry, C-SOPS has been involvedin the regulatory approval of some of the firstcontinuously manufactured solid dose products andis helping to shape the future of solid dose processdevelopment.
![Page 5: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/5.jpg)
Chronology of CM at Rutgers• 1998-2002 – F. Muzzio proposes CM to companies, CAMP, FDA• 2003 – Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex)• 2006 – C-SOPS funded – CM consortium becomes Test Bed 1• 2008 – Proof of concept achieved on CM with PAT• 2009 – NSF CM Commercialization Funds received ($1.8 million)• Feb 2011 – JnJ funding for Rutgers INSPIRE2 work approved ($1.9M)• Dec 2014 – Janssen/Rutgers partnership funded (3 more products) ($3.25M)• Feb 2015 – Modeling of Consigma 25 approved ($2 M)• Jan 2016 - C-SOPS receives $4M award from FDA to develop regulatory guidance elements on materials, PAT,
control • March 2016 - Presidential Report listed C-SOPS as top example of successful government invention in critical
emerging technology area of advance pharmaceutical manufacturing• April 2016 – FDA approval of Prezista® CM• June 2016 – USP and C-SOPS launch partnership on CM standards• July 2016 – CSOPS submits proposed draft guidance to FDA• December 2016 – 21st Century Cures Act – authorization for $25 M for CM • May 2017 – OSD Continuous Manufacturing in the Current Regulatory Landscape. Malta• December 2017 – CSOPS articulates Advanced Manufacturing Toolbox• March 2018 – Rutgers & GSK launch advanced manufacturing partnership• June/July 2018: $5.8M awarded by FDA for Industry 4.0, Continuous Biomanufacturing
![Page 6: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/6.jpg)
Interactions with FDA• FDA member of C-SOPS since 2007• Funded Continuous Process Modeling, 2013 ($500K)• Funded Material Properties and Process Control, 2015 ($4M)
– Week long training for 20 FDA employees in 2016, 27 in 2018
• Funded Industry 4.0, 2018 ($4M)• Funded continuous MAB manufacturing modeling, 2018 ($1.8M)• Three additional proposals in prep. for Nov. 2018: Knowledge management, Continuous HME for
opioids, Environmentally controlled material property testing facility• Major center proposal – target $50 million
– White paper in 2017– Authorization as part of 21st century cures– Visit to OPQ in Jan 2018– Visit by Commissioner Gottlieb and Congressman Pallone (115th congress H.R. 5568)– Preproposal submitted July 2018– Visit to OPQ in Aug 2018– Full proposal planned for Dec 2018
![Page 7: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/7.jpg)
M
M
PID
M
M
PID
M
M
PID
API feeder
Excipientfeeder
Lubricantfeeder
Co‐mill
Blender
Feed frame & Tablet Press
Continuous Manufacturing: integration of equipment, sensors, and controls
PAT
ProcessControl
![Page 8: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/8.jpg)
How we do itIntegrated Process Model
Experimental & Design Parameters
Material Properties
Unit Operations
e.g., Flow, Bulk Density, Angle of Repose
y f (x,a,t,m,n)dydt
g(x,a,t,m,n)
e.g., BlendersGMP Implementation
Non‐GMP Implementation
Feedback control
Feed forward control
Predictive Modeling
![Page 9: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/9.jpg)
Rational process design – 12 steps
1. Rough conceptual design2. Material property characterization3. Specification of individual unit operations4. Develop unit operation models5. Develop integrated model of open loop system6. Examine open loop performance7. Develop PAT methods8. Implement open loop kit with PAT and IPCs (OLIF)9. Design sensing and control architecture10. Develop integrated model of closed loop system (CLIF)11. Characterize closed loop performance (Validation)12. Optimize process performance
![Page 10: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/10.jpg)
Advanced Manufacturing Toolbox
Sensors/data analytics
Material Properties
Process Modeling
Process Control
Process Integration
Pharmaceu
ticals
Catalysts
Food
produ
cts
Faculty
, Stud
ents,
Post docs
Spon
sor
technical
person
nel
Adv. Man. Toolbox
RTQA / Sensor toolbox
Mat. Prop. Library
Modeling library
Control toolboxes, QbC
Integration toolbox
Cosm
etics
Batteries
ToolsImplementation methods
Quality Assurance
Demonstrated PlatformsManufacturing Science Process Understanding
KnowledgeProcess Science
Scientific leadership
Trained scientists
![Page 11: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/11.jpg)
Step 1: Develop a realistic plan
- Which product(s)?- Which platforms?- Flexible or dedicated?- How much sensing and control?- How much modeling?
Outcome: Select a first system, implement it, gain experience, bring new core capabilities into company
Implementing Continuous Manufacturing
![Page 12: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/12.jpg)
Step 2: Characterize material properties
- Which materials?- Which measurements?- How will the information be used?
- Models- Algorithms
- How will the information be maintained?
Outcome: create a systematic program to characterize materials that becomes a knowledge reservoir
Implementing Continuous Manufacturing
![Page 13: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/13.jpg)
Tablet Press
Lubricant
Feeders
M
API
Mill
Blender
13
M
Failure Mode
M
M
M
M
EX
M
EX
M
System Response
Flow Rate Set Point divergence
Q3: Are agglomerates present?
Q4: Can blend homogeneity be achieve?
Q7: Can we get tablets at target dissolution at reasonable high flow rate?
Flow rate variability
Related Material Properties
Q2: Can each ingredient be fed with variability below certain threshold?
Q1: Can each ingredient be fed at the required flow rate? Density, Permeability
Cohesion, Compressibility, Stickiness
Fail to comply hardness
Q6: Can we get tablets at target hardness at reasonable high flow rate?
Q5: Are blend flow properties good enough to support Weight Uniformity?
Agglomerates Electrostatics, Surface Energy, Adhesion, PSD
PSD, Adhesion, Cohesion, Electrostatics, Surface Energy
Chocking, Jamming, Discontinuous flow
Blend Cohesion, Density, Compressibility
Content uniformity/ Blend RSD
Blend Lubrication, Bonding, Plasticity, Elasticity.
Fail to comply dissolution
Blend Lubrication, Bonding, Plasticity, Elasticity, PSD,
crystallinity.
![Page 14: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/14.jpg)
Screw Coating and “sticky” powders
Coating of the screws reduces the space available material that can be fed and reduces the capacity of the feeder.
![Page 15: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/15.jpg)
Environmentally Controlled Powder Testing System
• Layout is a set of glove boxes with controlled humidity, temperature, pressure, N2 blanket
• Samples are conditioned in first box, then travel as needed to perform required tests
• Performance in process equipment is tested for conditioned samples
Conditioning: target moisture content, shear,
PSD
Density, picnometry, flow
propertiesp
Electrostatics, dipolar m
oment
charge acquisitionim
pedance,
Segregation, W
ettability
Surface energyVPE
Process Equip.
CompactabilitySolid state rheology
Air, Moisture, T, N2, Pressure
Sample
Sample
Sample Storage
![Page 16: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/16.jpg)
Step 3 and 4: Unit Operations Characterization and Modeling- Identify all unit operations and transitions- Obtain performance databases for relevant materials- Develop/adapt dynamic models for all relevant unit operations
- A lot of models already available- Models incorporate IPCs- Expertise available through partners
Outcome: create a model library that is a reservoir of process knowledge
16
Implementing Continuous Manufacturing
![Page 17: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/17.jpg)
Investigate Process Variables for Models
Model variable selection is based on the understanding of critical unit operation process parameters, variables and responses
Phenomenological model inputs are design parameters and operating variables. Unit responses are the model outputs
Selecting Process Variables for Models
![Page 18: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/18.jpg)
Unit Operation Model Development
MATERIAL INPUTS
PROCESS OUTPUTS
Granular Material BlendsWith many properties
Critical Process ParametersVariables affecting outputs
Semi-Empirical ModelsRelationship - process inputs and outputs
PROCESS MODELS
Understanding the effect of process inputs and material properties to process outputs is a critical step for moving towards in silico modeling and predictability
PROCESS INPUTS
Product PropertiesVary based on inputs
Empirical ModelsCorrelate material to model parameters
MATERIAL MODELS
M
M
We repeat these experiments many times, but we ought to collect this data and make it valuable
Modeling in Pharmaceutical Manufacturing
![Page 19: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/19.jpg)
Steps 5 and 6: Create and Validate Open Loop Integrated Flowsheet Model (OLIF model)- Create integrated dynamic model of entire line
- Tools already available from PSE and Aspen- Expertise available at partners
- Validate OLIF by comparison to experiments- Identify critical material attributes, critical process parameters, critical product
quality attributes- Determine feasible space
Outcomes: Understand interactions between unit operations, define critical variables to be monitored and controlled, establish operational space
19
Implementing Continuous Manufacturing
![Page 20: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/20.jpg)
2.9
3
3.1
3.2
100 150 200
API flow rate
Dynamic simulation
Time [s]
[kg/h]
Temporal variations due to refill
M
M
PID
M
M
PID
M
M
PID
API feeder
Excipientfeeder
Lubricantfeeder
Co‐mill
Blender
Feed frame & Tablet Press
Integrated flowsheet modeling
![Page 21: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/21.jpg)
Time [s]
Wt%
of A
PI
Dynamic simulation
Variations dampened in the blender
M
M
PID
M
M
PID
M
M
PID
API feeder
Excipientfeeder
Lubricantfeeder
Co‐mill
Blender
Feed frame & Tablet Press
Flowsheet modeling
![Page 22: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/22.jpg)
Steps 7 and 8: Integrate line, specify and implement sensors- Integrate physical line- Select and validate measurement systems
- Specify chemometric models for spectroscopic measurements- Validate in the line
- Identify process information data streams- Implement data analytics- Incorporate sensors and IPCs into OLIF model
Outcome: Ability to monitor material properties, process parameters, product quality in real time
22
Implementing Continuous Manufacturing
![Page 23: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/23.jpg)
23
Implementing Continuous Manufacturing
Sensor Critical Quality Attribute (CQA)
Ultrasound (US) and Laser Triangulation (LT)
Tablet thickness, hardness, Tensile strength - tablets
NIR spectroscopy Composition, Content uniformity – powders, tablets
Raman spectroscopy Composition, Contentuniformity, crystalline vs amorphous – powders, tablets
Raman Imaging (3D) Material distribution (eg. agglomeration), particle size –powders, tablets
Eyecon Particle Size Distribution (PSD), particle shape
Thermal Imaging Compaction, defects
X-Ray Structure, crystallinity, density distribution, mass flow
Terahertz (THz) Spectroscopy & Imaging
Tablet (internal layers)thickness, defects, material distribution
Feedback control
Feedforward control
![Page 24: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/24.jpg)
General Dissolution Prediction Methodology
Define target condi ons
0
50
100
150
0 20 40 60 80100120
Drugrelease%
Time/min
y = 0.9833x R² = 0.86308
0
50
100
150
200
250
300
0 50 100 150 200 250 300
α p
red
icte
d
α reference
Reference vs predicted
0 20 40 60 80
100
0 20 40 60 80 100 120 % Drug Dissolved
Time (min)
reference predic on
f2=79.13
Iden fy dissolu on mechanism
![Page 25: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/25.jpg)
1. APAP – 1st demonstration formulation (IR)2. Commercial Product (IR)3. PEO – 2nd demonstration formulation (SR)
Three Case Studies:
![Page 26: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/26.jpg)
26
Case Study 1 Predicting individual tablet dissolution profile
Reference: actual dissolution profilesPredicted: NIR PCs
![Page 27: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/27.jpg)
40
50
60
70
80
90
100
110
0 10 20 30 40 50 60 70
API %
rele
ased
Dissolution time (min)
Predicted vs Reference
Run 12- Pred Run 12-Ref
Case Study 2: Commercial IR product
![Page 28: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/28.jpg)
Case Study 3: 24 h release from PEO matrix
• Results demonstrated that individual tablet dissolution can be predicted with high accuracy
• This can be extended to more complex formulations
![Page 29: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/29.jpg)
Integrated product, process, analytical development
![Page 30: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/30.jpg)
Steps 9, 10, 11: Supervisory Process Control - Use OLIF to define and specify supervisory control architecture
- Control loop structure- Controller type- Controller parameter
- Implement selected control architecture to create Closed Loop Integrated Flowsheet (CLIF) model.
- Implement and evaluate accuracy and effectiveness of implemented control architecture in physical line
Outcome: Real time quality control
30
Implementing Continuous Manufacturing
![Page 31: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/31.jpg)
31
Implementing Continuous Manufacturing
31
Tablet Press
Blender
Feeders
mill
API
M
M
M
M
M
M
M
M
Content/DensityBlend Uniformity
NIR, Raman
LT
Thickness
Density
US
Hardness
NIR
Dissolution (check)
Feed forward control
Force
Weight
Compression Gap
Cross‐check
Content (check)
Feedback control
Feed forward control
![Page 32: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/32.jpg)
Advanced hybrid MPC-PID control system
32Control variables: API composition; Powder level; Tablet weight; Tablet hardness
3
6
4
5
2
1
RSD
Turret speed
![Page 33: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/33.jpg)
Steps 12: Runtime Optimization - Define outcomes to be optimized (productivity, quality, cost)- Implement optimization methods in CLIF - Search for optimum- Confirm optimization in physical line
Outcome: optimized system
33
Implementing Continuous Manufacturing
![Page 34: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/34.jpg)
Enabling a different future
34
Sensors/data analytics
Material Properties
Process Modeling
Process Control
Process Integration
Pharmaceu
ticals
Catalysts
Food
produ
cts
Cosm
etics
Batteries
Material PropertyDatabase
+ Process Models
Predictive Material
Performance
Meaningful Materials
Specifications
Sensors + Process Control
Predictive Process Design
Optimum Process
PerformanceOptimum Product
Quality
MaximumProfit
Process Integration Methods
![Page 35: Quality Control Strategies in Continuous Manufacturingccpmj.org/downloads/3_Prof.Muzzio(en).pdf · • 2003 –Rutgers forms CM consortium (Pfizer, Merck, GEA, Apotex) • 2006 –C-SOPS](https://reader035.fdocuments.in/reader035/viewer/2022071004/5fc089a753cc495a364ba60c/html5/thumbnails/35.jpg)
• Contact Information:• [email protected], [email protected], • 732-735-8618, • https://www.linkedin.com/in/fjmuzzio/
Questions?